Eyenuk Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 34

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $26.9M

  • Investors
  • 7

Eyenuk General Information

Description

Developer of an artificial intelligence eye screening technology designed for autonomous disease detection, risk assessment, and disease surveillance. The company's technology provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation and analyzes patient's retinal images acquired using an integrated fundus camera, enabling patients to screen their eyes to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer's disease.

Contact Information

Website
www.eyenuk.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Corporate Office
  • 5850 Canoga Avenue
  • Suite 250, Woodland Hills
  • Los Angeles, CA 91367
  • United States
+1 (818) 000-0000

Eyenuk Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eyenuk Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC (Series A) 23-Aug-2022 $26.9M 0000 000.00 Completed Generating Revenue
12. Grant 01-Jul-2020 00000 00.00 Completed Generating Revenue
11. Grant 30-Sep-2019 00000 00.00 Completed Generating Revenue
10. Grant 01-Jun-2018 00000 00.00 Completed Generating Revenue
9. Grant 01-Jun-2018 00.00 00.00 Completed Generating Revenue
8. Seed Round 30-Apr-2018 00.000 00.00 000.00 Completed Generating Revenue
7. Seed Round 31-Oct-2017 00.000 00.000 00.00 Completed Clinical Trials - General
6. Grant 01-Aug-2016 000 00.00 Completed Clinical Trials - General
5. Seed Round 19-Jul-2016 $1.5M $1.5M 000 Completed Clinical Trials - General
4. Grant 01-Jan-2016 $7M Completed Product In Beta Test
To view Eyenuk’s complete valuation and funding history, request access »

Eyenuk Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-2 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A-1 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series S-2 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series S-1 289,276 $0.000100 6% $5.37 $5.37 1x $5.37 3.23%
Series S 348,547 $0.000100 6% $4.49 $4.49 1x $4.49 3.89%
To view Eyenuk’s complete cap table history, request access »

Eyenuk Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an artificial intelligence eye screening technology designed for autonomous disease detection, risk assessm
Diagnostic Equipment
Los Angeles, CA
34 As of 2023
0000
00.00 0000-00-00
00000000000 0000

000000

, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
0000000000 000000000
Coralville, IA
000 As of 0000
00000
0000 0000-00-00
00000000000 00000

000000

t labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitat
0000000000 000000000
Pensacola, FL
00 As of 0000
000.00
000000000 - 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eyenuk Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Digital Diagnostics Venture Capital-Backed Coralville, IA 000 00000 00000000000 00000
Intelligent Retinal Imaging Systems Venture Capital-Backed Pensacola, FL 00 000.00 000000000 - 000.00
Icare ( Diagnostic Equipment) Formerly VC-backed Vantaa, Finland 000 00000 000000&0 00000
Notal Vision Venture Capital-Backed Manassas, VA 00 00000 00000000000 00000
Retmarker Formerly VC-backed Coimbra, Portugal 0 00000 000000&0 00000
You’re viewing 5 of 7 competitors. Get the full list »

Eyenuk Patents

Eyenuk Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220079436-A1 Systems and apparatuses for three-dimensional eye imaging for screening, monitoring, and diagnosis of diseases Pending 17-Sep-2020 00000000
US-20220075509-A1 Graphical element detection using a combined series and delayed parallel execution unified target technique, a default graphical element detection technique, or both Active 08-Sep-2020 00000000
US-11281362-B1 Graphical element detection using a combined series and delayed parallel execution unified target technique, a default graphical element detection technique, or both Active 08-Sep-2020 00000000 000
US-20210353141-A1 Systems, methods, and apparatuses for eye imaging, screening, monitoring, and diagnosis Pending 26-Nov-2018 0000000000
US-20210353143-A1 Systems and methods for automated end-to-end eye screening, monitoring and diagnosis Inactive 27-Dec-2017 A61B3/12
To view Eyenuk’s complete patent history, request access »

Eyenuk Executive Team (4)

Name Title Board Seat Contact Info
Kaushal Solanki Ph.D Founder, Chief Executive Officer & Board Member
Paul Praino Chief Commercial Officer
You’re viewing 2 of 4 executive team members. Get the full list »

Eyenuk Board Members (6)

Name Representing Role Since
Kaushal Solanki Ph.D Eyenuk Founder, Chief Executive Officer & Board Member 000 0000
Manish Potti Eyenuk Board Member 000 0000
Marie-Louise Little Self Board Member 000 0000
Robert Binney Self Chairman 000 0000
Zina Besse Ph.D AXA Investment Managers Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Eyenuk Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eyenuk Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
A&C Foelsgaard Alternativer Venture Capital Minority 000 0000 000000 0
AXA Investment Managers Asset Manager Minority 000 0000 000000 0
Kendall Capital Partners Venture Capital Minority 000 0000 000000 0
KOFA Healthcare Corporation Minority 000 0000 000000 0
T&W Medical Corporation Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »